The 2025 Annual
PRIMO Meeting
- Practical considerations of applying biomarkers and targeted therapy
- Integration of immunotherapy, with a focus on novel management approaches
- Patient selection, as well as timing and sequencing of therapy
- Dealing with important trends, such as big data and defining value in cancer care
Join us in honoring the 2025 Women in Oncology Award winner
Julie M. Vose, MD, MBA
Session Chair: Julie M. Vose, MD, MBA
Tom Martin, MD
Susan M. O’Brien, MD
Eunice S. Wang, MD
Kami J. Maddocks, MD
Session Co-Chairs: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE and Shane Y. Morita, MD, MS, PhD, FACS
10-minute presentation and 15 minute multi-disciplinary discussion
Discussants:
Daniel Ahn, DO, MS
Chandler H. Park, MD, MSc, FACP
Jorge J. Nieva, MD
Michael E. Carney, MD, FACOG
Kristen Chun, RN, BSN, MBA/HCM
Thomas Samuel Shomaker, MD, JD
Naoto T. Ueno, MD, PhD
Session Chair: Daniel Ahn, DO, MS
Midhun Malla, MD, MS
Session Chair: Sanjiv S. Agarwala, MD, FASCO
Session Chair: Luis E. Raez, MD, FACP, FASCO
Luis E. Raez, MD, FACP, FASCO
1 Case Each:
Jyoti D. Patel, MD, FASCO
Tejas Patil, MD
Jorge J. Nieva, MD
Session Chair: Ulka Vaishampayan, MD
Chandler H. Park, MD, MSc, FACP
Session Chair: Don Dizon, MD, FACP, FASCO
Don Dizon, MD, FACP, FASCO
Vincente Valero, MD, FACP
Mark Pegram, MD
Joyce O’Shaughnessy, MD
Hope Rugo, MD, FASCO
Julie Vose, MD, MBA
We acknowledge commercial support from Taiho Oncology, Exelixis, Pfizer, AstraZeneca, and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Registration
| Registration Type |
Early Ends Augustus 31, 2024 |
Regular Sep-Dec 31, 2024 |
Late Jan 1-Feb 5, 2025 |
One-day pass |
|---|---|---|---|---|
|
Physician |
$445.00 |
$545.00 |
$645.00 |
$250.00 |
|
Allied Health |
$345.00 |
$445.00 |
$545.00 |
$200.00 |
|
Resident/Fellow |
$295.00 |
$395.00 |
$495.00 |
$175.00 |
|
Industry: Professional of Exhibiting Company |
$1,500.00 |
$2,000.00 |
$2,500.00 |
N/A |
|
Industry: Non-exhibiting Company |
$5,000.00 |
$5,000.00 |
$5,000.00 |
$5,000.00 |
Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.
Target Audience
This activity has been designed to meet the educational needs of Academic and Community Practitioners, from all oncology specialties, to include physicians, nurses and nurses practitioners, physician associates, pharmacists and other healthcare professionals treating all disease sites involved in the care or patients with cancer.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
- Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
- Identify patients who are appropriate candidates for targeted and immunologic therapies;
- Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
- Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.
PRIMO 2020
at a Glance
The Practical Recommendations in Immuno and Molecular Oncology Meeting is a unique opportunity to receive CE credits while staying ahead of the latest advances in immuno and molecular oncology.
The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.
Accredited by:
Accreditation and Credit Statements
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 12.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physician
The Medical Educator Consortium designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”
Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)
Nursing
The Medical Educator Consortium designates this activity for 12.00 contact hours.
Pharmacist
This Application-based activity has been approved for 12.00 contact hours (1.20 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-25-001-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
Physician Associate
The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
DISCLOSURE POLICY
The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and the ACCME Standards for Integrity and Independence in Accredited Continuing Education. As a Joint Accreditation (JA) provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All persons that will be in a position to control the content of the CE Activity are required to disclose all relevant financial relationships, regardless of the amount, that they have had in the past 24 months with ineligible companies. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. A Disclosure Index document outlining this information will be made available to participants prior to the educational activity. The source of all commercial support from ineligible companies will also be disclosed to learners prior to the beginning of the educational activity. CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.